Novo Nordisk wins EU approval for Wegovy oral obesity pill
NVO•EU approves Wegovy pill and higher-dose injection
Novo Nordisk secured European Commission marketing authorization for Wegovy pill, a once-daily oral semaglutide 25 mg for adult weight management.
The EU also cleared a single-dose pen version of the higher-dose Wegovy 7.2 mg injection for obesity.
Novo Nordisk cited OASIS 4 trial data showing about 17% mean weight loss for the pill versus 3% for placebo.
